Development based in Switzerland

Empowered by

Innovative

DNA-based

technology

Our DNA-based design platform is used to ensure efficient generation and rapid development of novel vaccines for SARS-CoV-2, other viral diseases, and cancer.

RocketVax AG

Swiss biotech startup based in Basel, established in 2020.

The company brings together both scientific and operational expertise from various institutions in Switzerland and Germany and aims to become a world leading centre of excellence for novel vaccine development.

Our mission is to

Address

pressing global

health challenges

Board of Directors

Dr. Jeanette Wood

Chairwoman and Non-executive Board Member

Dr. Jeanette Wood is an accomplished scientist with extensive experience in all aspects of drug discovery across multiple disease areas, including cancer.

Dr. Vladimir Cmiljanovic

Vice-Chairman and Executive Board Member

Dr. Vladimir Cmiljanovic is one of Switzerland's leading serial biotech entrepreneurs, a medicinal chemist, and a cancer scientist with more than fifteen years of experience in oncology drug development.

Dr. Natasa Cmiljanovic

Executive Board Member

Dr. Natasa Cmiljanovic, Chief Scientific Officer and Founder, is a medicinal chemist and clinical scientist with more than ten years of experience in oncology drug development. She is the co-author of various scientific articles and abstracts and inventor of numerous patents.

Dr. Thomas Ladner

Non-executive Board Member

Dr. Thomas Ladner, Board Member and Secretary of the Board, became in 2002 the youngest partner at Meyerlustenberger Lachenal, one of Switzerland's leading law firms, where he specialized in private equity and M&A. From 2000 to 2004, Thomas lectured on corporate law and contract law at the University of St. Gallen (Switzerland), from where he also holds a Ph.D.

Marco Illy

Non-executive Board Member

Marco Illy is an investment banker who spent 30 years with Credit Suisse. After holding various positions including Head of the Investment Banking and Securities division of Credit Suisse in Switzerland, he was co-head of the European Investment Banking Coverage in London and in 2005, he was appointed head of Credit Suisse’s investment banking business in Germany.

Christoph Brutschin

Non-executive Board Member

Christoph Brutschin obtained his economic degrees at the University of applied sciences of Zürich and at the University of Fribourg. He held positions with PWC and maxit AG (Switzerland) before becoming a headmaster of the Basel commercial vocational training college.